Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1)

Human and Experimental Toxicology

Volumn 17, Issue 2, 1998, Pages 93-104

  Duncan, R ^a   Coatsworth, J K ^b   Burtles, S ^c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b BIBRA INTERNATIONAL   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Drug targeting; HPMA copolymer doxorubicin; PK1; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; COPOLYMER; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE MARROW DEPRESSION; CLINICAL CHEMISTRY; CONTROLLED STUDY; HEMATOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PROXIMAL TUBULE; LEUKOCYTE COUNT; LIVER INJURY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TESTIS ATROPHY; THROMBOCYTE COUNT; THYMUS ATROPHY; TIME; TOXICITY TESTING; URINALYSIS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; DOXORUBICIN; DRUG CARRIERS; INJECTIONS, INTRAVENOUS; LETHAL DOSE 50; MALE; MICE; ORGAN SIZE; POLYMETHACRYLIC ACIDS; RATS; RATS, WISTAR;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0031933130     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032798678908378     Document Type: Article

References (30)

1. Duncan R. Polymer therapeutics for tumour specific delivery. Chemistry & Industry 1997; 7: 262-264.
2. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 1992; 3: 175-210.
3. Duncan R, Dimitrijevic S, Evagorou EG. The role of polymer conjugates in the diagnosis and treatment of cancer. S.T.P. Pharma Sci 1996; 6: 237-263.
4. Vasey PA, et al. Clinical and Pharmacokinetic Phase I Study of PK1 (HPMA co-polymer doxorubicin). Annals in Oncology 1996; 7: 97.
5. Duncan R, Rejmanova P, Kopecek J, Lloyd JB. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim Biophys Acta 1981; 678: 143-150.
6. Rejmanova P, Kopecek J, Duncan R, Lloyd JB. Stability in plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials 1985; 6: 45-48.
7. Duncan R et al. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Brit J Cancer 1988; 57: 147-156.
8. Duncan R et al. Polymers containing enzymatically degradable bonds 7. Design of oligopeptide side chains in poly N-(2-hydroxypropyl)methacrylamide copolymers to promote efficient degradation by lysosomal enzyme. Makromol Chem 1984; 184: 1997-2008.
9. Cassidy J et al. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem Pharmacol 1989; 38: 875-879.
10. Seymour LW et al. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. British J Cancer 1994; 70: 636-641.
11. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit Rev Ther Drug Carrier Sys 1989; 6: 193-210.
12. Shockley TR et al. A quantitative analysis of tumour specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumour antigen expression levels. Cancer Res 1992; 52: 357-366.
13. Young TK et al. Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol 1991; 29: 105-111.
14. Rihova B et al. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Immunogenicity, effect of haematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 1989; 10, 335-342.
15. Duncan R et al. Preclinical evaluation of polymer-bound doxorubicin. J Controlled Rel 1992; 19: 331-346.
16. Duncan R et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Brit J Cancer 1987; 55: 165-174.
17. Young RC, Ozols RF, Myers CE. The anthracyline antineoplastic drugs. New Engl J Med 1981; 305: 153-159.
18. Freidman MA, Carter SB. Serious toxicities associated with chemotherapy. Semin Oncol 1978; 5: 193-202.
19. Launchbury AP, Habboubi N. Eprirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Revs 1993; 19: 197-228.
20. Bronchud MH et al. Phase I/II study of recombinant human granulocyte colony stimulating factor in patients receiving intensive chemotherapy for non small cell lung cancer. Br J Cancer 1987; 56: 809-813.
21. Basser RL, Green MD. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Revs 1993; 19: 57-77.
22. Northfelt DW et al. Pharmacokinetics (PK), tumour localisation (TL) and safety of Doxil™ (liposomal doxorubicin in AIDS patients with Kaposi's sarcoma (AIDS-KS). Proc ASCO 1993; 12: 51.
23. Money-Kyrle JF et al. Liposomal daunorubicin in advanced Kaposi's sarcoma: A phase II study. Clin Oncol 1993; 5: 367-371.
24. Camaggi CM et al. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. Cancer Chemother Pharmacol 1988; 21: 221-228.
25. Hopewell JW, Duncan R, Wilding D. Preclinical studies of cardiotoxicity of PK2: A novel polymeric antitumour agent. Br J Cancer 1997, submitted.
26. Seymour LW et al. Pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol 1990; 39: 1125-1131.
27. Fraier D et al. A sensitive procedure for quantitation of free and N-(2-hydroxypropyl)-methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxombicinone, in human plasma and urine by reverse-phase HPLC with fluorometric detection. J Pharm Biomed Anal 1995; 13: 625-640.
28. Mazue G et al. Anthracyclines: Review of genotoxicity and carcinogenicity studies. Int J Oncol 1996; 8: 525-536.
29. Working PK, Dayan AD. Pharmacological-toxicological expert report on Calelyx™. Human Exp Tax 1996; 15: 752-785.
30. Vasey PA et al. Phase I clinical and pharmacokinetic study of PK1 (HPMA-co-polymer doxorubicin): First member of a new class of chemotherapeutic agents-drug-polymer conjugates. J Clin Oncol 1997 submitted.